Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate whether intensive metabolic intervention of PCOS women before pregnancy can improve pregnancy outcome.Besides, the investigators aim to investigate the best therapy strategy of metabolic intervention before pregnancy.The investigators plan to recruit PCOS women at childbearing age. By using acarbose, GLP-1 analogue, berberin et al. the investigators will intervent the participants' metabolic statues for 3 months before pregnancy and to compare outcome in each group.
To investigate whether intensive metabolic intervention of PCOS women before pregnancy can improve pregnancy outcome.Besides, the investigators aim to investigate the best therapy strategy of metabolic intervention before pregnancy.The investigators plan to recruit PCOS women with IGR / DM not effective of metformin treatment at childbearing age. By using acarbose, GLP-1 analogue, berberin et al. the investigators will intervent the participants' metabolic statues for 3 months before pregnancy and to compare outcome in each group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control | Other | metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance |
|
| acarbose | Experimental | metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months |
|
| Exenatide | Experimental | metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months |
|
| Orlistat | Experimental | metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acarbose 100 MG | Drug | for metformin uneffective subjects, using acarbose for 3 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement of pregnant rate after intensive metabolic intervention | To compare the pregnant rate of four groups after treatment | up to 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement of obsorbtion rate after intensive metabolic intervention | To compare the obsorbtion rate of four groups after treatment | up to 24 weeks |
| Improvement of stillborn foetus rate after intensive metabolic intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tao Tao, MD | Contact | 86-13817701776 | taotaosh76@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Tao Tao, MD | RenJi Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Renji Hospital Department of Endocrinology and Metabolism | Shanghai | Shanghai Municipality | 200127 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018149 | Glucose Intolerance |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020909 | Acarbose |
| D000077270 | Exenatide |
| D000077403 | Orlistat |
| D008687 | Metformin |
| ID | Term |
|---|---|
| D014312 | Trisaccharides |
| D009844 | Oligosaccharides |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Exenatide | Drug | for metformin uneffective subjects, using Exenatide for 3 months |
|
| Orlistat | Drug | for metformin uneffective subjects, using Orlistatfor 3 months |
|
| Metformin | Drug | metformin effective subjects,act as control group |
|
|
To compare the stillborn foetus rate of four groups after treatment
| up to 24 weeks |
| Improvement of hyperandrogenism | To compare the free androgen index of three groups after treatment | up to 24 weeks |
| Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation | To compare the intravenous blood glucose of three groups after treatment | up to 24 weeks |
| Improvement of triglyceride | To compare the circulating triglyceride of three groups after treatment | up to 24 weeks |
| D010455 |
| Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D014688 | Venoms |
| D045424 | Complex Mixtures |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |